Bendamustine as a model for the activity of alkylating agents

Future Oncology

Volumn 4, Issue 3, 2008, Pages 323-332

  Apostolopoulos, Christos ^a   Castellano, Leandro ^a   Stebbing, Justin ^a   Giamas, Georgios ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Alkylating agent; Bendamustine; Cancer; Drug discovery; Lymphoma; Treanda

Indexed keywords

ALKANESULFONIC ACID DERIVATIVE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; AZIRIDINE DERIVATIVE; BENDAMUSTINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NITROSOUREA; OXAZAPHOSPHORINE DERIVATIVE; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; SDX 105; SONE; TEMOZOLOMIDE; TRENDA; TRIAZENE DERIVATIVE; UNINDEXED DRUG; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANEMIA; APOPTOSIS; ARTICLE; BILE DUCT CANCER; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CD4 CD8 RATIO; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; CYTOTOXICITY; DNA REPAIR; DRUG ACTIVITY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG SMALL CELL CANCER; LYMPHOCYTOTOXICITY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PATIENT CARE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; UNITED STATES; VOMITING; XEROSTOMIA;

ALKYLATING AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS;

EID: 47249130766     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.3.323     Document Type: Article

References (62)

1. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
2. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
3. Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10(2), 104-111 (2005).
4. Ingelman-Sundberg M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 89-104 (2004).
5. Marsh S, McLeod HL: Cancer pharmacogenetics. Br. J. Cancer 90, 8-11 (2004).
6. Rushmore TH, Kong AN: Pharmacogenomics, regulation and signaling pathways of Phase I and II drug metabolising enzymes. Curr. Drug Metab. 3(5), 481-490 (2002).
7. Xu C, Li CY, Kong AN: Induction of Phase I, II and III drug metabolism/ transport by xenobiotics. Arch. Pharm. Res. 28(3), 249-268 (2005).
8. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 23(1), 1-8 (2004).
9. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C: Identifying DNA methylation biomarkers of cancer drug response. Am. J. Pharmacogenomics 5(4), 223-232 (2005).
10. 6-methylguanine-DNA-methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lymphocytes of tobacco smokers. Pharmacogenet. Genomics 17(9), 743-753 (2007).
11. Zhang J, Tian Q, Zhu YZ, Xu AL, Zhou SF: Reversal of resistance to oxazaphosphorines. Curr. Cancer Drug Targets 6(5), 385-407 (2006).
12. Xie H, Griskevicius L, Stahle L et al.: Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci. 27(1), 54-61 (2006).
13. Nakajima M, Komagata S, Fujiki Y et al.: Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics 17(6), 431-445 (2007).
14. Murphy MP: Current pharmacogenomic approaches to clinical drug development. Pharmacogenomics 1(2), 115-123 (2000).
15. Oscarson M: Pharmacogenetics of drug metabollsing enzymes: importance for personalised medicine. Clin. Chem. Lab. Med. 41(4), 573-580 (2003).
16. Raghavan D: Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97(Suppl. 8), 2083-2089 (2003).
17. Toffoli G, Cecchin E: Pharmacogenetics and stomach cancer: an update. Pharmacogenomics 8(5), 497-505 (2007).
18. Knoche E, McLeod HL, Graubert TA: Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics 7(5), 719-729 (2006).
19. Choi JY, Nowell SA, Blanco JG, Ambrosone CB: The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 7(4), 613-624 (2006).
20. Biason P, Toffoli G: Sarcomas and pharmacogenetics. Pharmacogenomics 6(6), 585-601 (2005).
21. Aplenc R, Lange B: Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br. J. Haematol. 125(4), 421-434 (2004).
22. Gandhi V: Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin. Oncol. 29(Suppl. 4), 4-11 (2002).
23. Hartmann M, Zimmer C: Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim. Biophys. Acta 287(3), 386-389 (1972).
24. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S: Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4), 415-421 (1996).
25. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR: Cytotoxic efficacy of bendamustine-in human leukemia and breast cancer cell lines. J. Cancer Res. Clin. Oncol. 128(5), 271-278 (2002).
26. Chow KU, Boehrer S, Geduldig K et al.: In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 86(5), 485-493 (2001).
27. Chow KU, Sommerlad WD, Boehrer S et al.: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87(1), 33-43 (2002).
28. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E: In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin. Oncol. 29(4 Suppl. 13), 12-14 (2002).
29. Schwänen C, Hecker T, Hübinger G et al.: In vitro evaluation of bendamustine induced apoptosis in B-chronic iymphocytic leukemia. Leukemia 16(10), 2096-2105 (2002).
30. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R: Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J. Cancer Res. Clin. Oncol. 134(2), 245-253 (2007).
31. Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE: Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim. Biophys. Acta 1497(2), 215-226 (2000).
32. Staib P, Lathan B, Schinköthe T et al.: Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivlty-index Ci. Adv. Exp. Med. Biol. 457, 437-444 (1999).
33. Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober J: Salvage chemotherapy for metastatic breast cancer: results of a Phase II study with bendamustine. Ann. Oncol. 18(12), 1981-1984 (2007).
34. Eichbaum MH, Schuetz F, Khbeis T et al.: Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a Phase II study. Anticancer Drugs 18(8), 963-968 (2007).
35. Höffken K, Merkle K, Schönfelder M et al.: Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a Phase II study. J. Cancer Res. Clin. Oncol. 124(11), 627-632 (1998).
36. von Minckwitz G, Chernozemsky I, Sirakova L et al.: Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC), a Phase III prospective, randomised, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drug 16(8), 871-877 (2005).
37. Ruffert K: Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil. Zentralbl Chir. 123(Suppl. 5), 156-158 (1998).
38. Schwänen C, Karakas T. Bergmann L: Bendamustine in the treatment of low-grade non-Hodgkin's lymphomas. Onkologie 23, 318-224 (2000).
39. Robinson KS, Williams ME, Cohen P et al.: Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: a Phase II study. Blood 106, 271A (2005).
40. Friedberg JW, Cohen P, Cheson BD et al.: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a Phase II multicenter, single-agent study. J. Clin. Oncol. 26(2), 204-210 (2008).
41. Bremer K: High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J. Cancer Res. Clin. Oncol. 128(11), 603-609 (2002).
42. Rummel MJ, A1-Batran SE, Kim SZ et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 23(15), 3383-3389 (2005).
43. Herold M, Schulze A, Niederwieser D et al.: Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised Phase III trial. J. Cancer Res. Clin. Oncol. 132(2), 105-112 (2006).
44. Kath R, Blumenstengel K, Fricke HJ, Peters HD, Höffken K: Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma. Dtsch. Med. Wochenschr. 126(8), 198-202 (2001).
45. Weidmann E, Kim SZ, Rost A et al.: Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann. Oncol. 13(8), 1285-1289 (2002).
46. Heider A, Niederle N: Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 12(9), 725-729 (2001).
47. Weide R, Hess G, Köppler H et al.: High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter Phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma 48(7), 1299-1306 (2007).
48. Weide R, Pandorf A, Heymanns J, Köppler H: Bendamustine/ mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk. Lymphoma 45(12), 2445-2449 (2004).
49. Koenigsmann M, Knauf W, Herold M et al.: Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - a multicenter Phase I/II trial of the East German Society of Hematology and Oncology. Leuk. Lymphoma 45(9), 1821-1827 (2004).
50. Pönisch W, Niederwieser D: Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin. Oncol. 29(4 Suppl. 13), 23-26 (2002).
51. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H: The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90(9), 1287-1288 (2005).
52. Pönisch W, Mitrou PS, Merkle K et al.: Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomised Phase III study of the East German Study Group of Hematology and Oncology. J. Cancer Res. Clin. Oncol. 132(4), 205-212 (2006).
53. Balfour JA, Goa KL: Bendamustine. Drugs 61(5), 631-638; discussion 639-640 (2001).
54. Bottke D, Bathe K, Wiegel T, Hinkelbein W: Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol. 183(3), 128-132 (2007).
55. Köster W, Stamatis G, Heider A et al.: Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin. Drug Investig. 24(10), 611-618 (2004).
56. Köster W, Heider A, Niederle N et al.: Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J. Thorac. Oncol. 2(4), 312-316 (2007).
57. Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U: Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 55(1), 109-113 (2007).
58. Schoppmeyer K, Kreth F, Wiedmann M, Mössner J, Preiss R, Caca K: A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs 18 (6), 697-702 (2007).
59. Hartmann JT, Mayer F, Schleicher J et al.: Bendamustine hydrochloride in patients with refractory soft tissue sarcoma. A noncomparative multicenter Phase 2 study of the German sarcoma group (AIO-001). Cancer 110(4), 861-866 (2007).
60. Schrijvers D, Vermorken JB: Phase I studies with bendamustine: an update. Semin. Oncol. 29(4 Suppl. 13), 15-18 (2002).
61. Rasschaert M, Schrijvers D, van den Brande J et al.: A Phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumours. Anticancer Drugs 18(5), 587-595 (2007).
62. Schöffski P, Seeland G, Engel H et al.: Weekly administration of bendamustine: a Phase I study in patients with advanced progressive solid tumours. Ann. Oncol. 11(6), 729-734 (2000).